Takeda”s Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
Friday, 1 July 2022, 16:28:49
Takeda Pharmaceutical Co Ltd (NYSE: TAK ) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022. The data demonstrated positive results of Takhzyro (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to … Full story available on Benzinga.com
— Benzinga
Takeda’s TAKHZYRO (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
Friday, 1 July 2022, 00:01:00
Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 SPRING study (NCT04070326) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, demonstrating positive results of TAKHZYRO (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult
— Wallstreet:Online
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
Friday, 1 July 2022, 00:01:00
OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 SPRING study (NCT04070326) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, demonstrating positive results of TAKHZYRO® (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult and adolescent patients.1 There are currently
— Business Wire
Takeda to absorb unit Nihon”s business assets
Friday, 24 June 2022, 13:12:35
Takeda Pharmaceutical (TAK) said it will succeed to the rights and obligations related to research, development and manufacturing businesses of Plasma-Derived Therapies and other…
— Seeking Alpha
Takeda and Nintendo among Japanese firms quietly celebrating weak yen
Friday, 17 June 2022, 08:16:20
For Takeda Pharmaceutical, Japan”s biggest drugmaker, a weaker yen helps because 80% of its sales are overseas, said the firm”s CFO.
— The Japan Times
We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.
